Clinical Trials | October 23, 2025
Pimicotinib delivers lasting tumor responses and sustained symptom relief in TGCT patients
Global Phase 3 MANEUVER study highlights ongoing benefits and consistent safety profile
Global Phase 3 MANEUVER study highlights ongoing benefits and consistent safety profile
Acquisition aims to strengthen Merck's downstream process offering of advanced filtration and chromatography solutions
Several technologies for hemoglobinopathies are being transferred to commercial partners
Merck and Siemens signed new MoU extending their strategic partnership to accelerate digital transformation in the life science industry
Merck opens first climate-neutral manufacturing facility in Ireland
Biocytogen will provide proprietary, fully human antibodies derived from its RenMice platform for evaluation in Merck’s antibody-conjugated LNP services
He has successfully led the development of 15 approved drugs worldwide across various therapeutic areas over his more than 20-year career
Protein L is known as a “superantigen” because it can bind antibodies in unusual ways
Skyhawk Therapeutics enters into an option agreement to grant Merck KGaA, Darmstadt, Germany, exclusive global rights to drug candidates pursued under the collaboration upon option exercise
Projects 5X revenue growth by 2028, accelerates global market leadership and paves the way for IPO
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
